Padma Lakshmi, Endometriosis, and Compounded vs. Branded Treatment: What's Actually Likely

Who Padma Lakshmi Is and Why Her Endometriosis Story Matters

Padma Lakshmi is a television host, author, and model who spent roughly two decades not knowing why she had debilitating menstrual pain. She was finally diagnosed with endometriosis at 36. In 2009, she and endometriosis specialist Dr. Tamer Seckin co-founded the Endometriosis Foundation of America, turning her personal experience into a public-health mission. She has spoken openly about missing school, canceling work, and being dismissed by clinicians who told her that severe cramping was simply "normal."

Her story is not unusual. Endometriosis affects approximately 190 million women and girls worldwide, according to the World Health Organization. The average delay from symptom onset to confirmed diagnosis in the United States sits between 7 and 10 years, a gap driven by normalization of pain, limited clinician training, and the fact that definitive diagnosis historically required laparoscopic surgery.

Because Padma has not published her medical records, this article is deliberately framed as "what is clinically likely" based on her public statements, her age, and current evidence-based guidelines. This is journalism informed by clinical science, not speculation presented as fact.

What Endometriosis Actually Is, and Why Treatment Is Complicated

Endometriosis occurs when tissue similar to the uterine lining grows outside the uterus, most commonly on the ovaries, fallopian tubes, and pelvic peritoneum. That tissue responds to estrogen the same way endometrial tissue does: it proliferates, bleeds, and triggers inflammation. Over time, this cycle produces adhesions, scarring, and in many cases, infertility.

The Estrogen-Dependence Problem

Estrogen drives endometriosis. That single fact shapes every treatment decision. Most medical therapies work by reducing circulating estrogen or blocking its effects on lesion tissue. The tradeoff is that low-estrogen states cause bone loss, hot flashes, and cardiovascular changes, the same profile as menopause. Clinicians therefore aim for a "therapeutic window" of estrogen suppression that is low enough to quiet lesion activity but not so low that it causes harm.

Surgery Versus Medical Management

Surgical excision of lesions, when performed by a skilled excision specialist, reduces pain and improves fertility outcomes. The ASRM Practice Committee acknowledges that excision is superior to ablation for deep infiltrating disease. Medical management does not remove lesions; it suppresses their estrogen-driven activity. Most women with endometriosis use both over their lifetime.

What We Know from Padma's Public Statements

Padma has said in multiple interviews that she went years without a correct diagnosis, that her pain was severe enough to affect her ability to work and function during menstruation, and that surgery changed her quality of life. She has also described advocating for aggressive medical follow-up.

She has not, to date, publicly named specific medications she takes or has taken for endometriosis management. What she has made clear is that she believes in specialist-level care and in women demanding answers rather than accepting "just deal with it" responses from clinicians.

Her age, now in her mid-50s, means she is likely at or past the menopause transition. That shift changes the treatment equation in a specific way: after menopause, endogenous estrogen drops sharply, which often quiets endometriosis lesion activity. But it does not eliminate the disease, and in women on menopausal hormone therapy, estrogen add-back can reactivate symptoms.

Compounded vs. Branded: The Core Question

Compounded medications are not FDA-approved formulations. They are prepared by a compounding pharmacy for a specific patient based on a prescriber's order. Branded medications have gone through clinical trials, demonstrated efficacy and safety to the FDA, and are manufactured under standardized quality controls.

For endometriosis specifically, the branded-versus-compounded debate centers on a few drug categories.

GnRH Agonists and Antagonists: Branded Dominate This Space

The most potent pharmaceutical option for endometriosis suppression is the class of gonadotropin-releasing hormone (GnRH) agonists and antagonists.

GnRH agonists (leuprolide, sold as Lupron) work by initially stimulating and then downregulating the pituitary, driving estrogen to near-castrate levels. Lupron Depot is FDA-approved for endometriosis at 3.75 mg monthly or 11.25 mg every three months, typically for up to six months without add-back, or longer with add-back hormonal therapy. Compounded leuprolide exists but is not standard practice and would carry significant regulatory risk; no compounding pharmacy can replicate the depot injection formulation reliably.

GnRH antagonists are newer and more patient-friendly. Elagolix (Orilissa), approved by the FDA in 2018, is available as 150 mg daily for up to 24 months or 200 mg twice daily for up to six months, with dose-dependent hypoestrogenic side effects including 2-3% bone mineral density loss at one year at the higher dose. Relugolix combination tablet (Myfembree) was approved in 2022 and pairs a GnRH antagonist with low-dose estrogen and progestin to limit bone loss. These are proprietary formulations. No compounded equivalent exists.

For a woman of Padma's profile, prior use of Lupron or elagolix during her reproductive years is clinically plausible. Post-diagnosis, specialist-level endometriosis care almost always involves at least a trial of GnRH-based suppression if surgery alone is insufficient.

Progestins: Where Compounded Options Exist and Are Clinically Used

Progestins are the other major pillar of endometriosis medical management. They suppress endometrial and ectopic endometrial tissue by opposing estrogen. Options include:

• Norethindrone acetate (Aygestin), an oral progestin used off-label for endometriosis at 5 mg daily
• Medroxyprogesterone acetate (Depo-Provera), injectable, suppresses ovulation and menstruation
• The levonorgestrel IUD (Mirena), which delivers local progestin and often reduces endometriosis-related pain
• Dienogest (not yet FDA-approved in the U.S. But widely used in Europe and studied in multiple randomized controlled trials)

Compounded bioidentical progesterone (micronized progesterone, chemically identical to the branded Prometrium) is widely prescribed by integrative and reproductive endocrinologists. The question is whether it is effective for endometriosis lesion suppression. The evidence is mixed. Progesterone as a class can suppress lesion activity, but oral micronized progesterone at standard hormone therapy doses may not provide the same progestogenic load as synthetic progestins. A 2021 Cochrane review found that progestins and antiprogestogens significantly reduce endometriosis-associated pain compared with placebo, but most trial data used synthetic progestins rather than micronized progesterone.

Compounded progesterone is most clinically defensible for endometriosis in the add-back context: when a woman is on GnRH-based suppression and needs exogenous progesterone to protect bones and control hypoestrogenic symptoms, compounded micronized progesterone is a reasonable, lower-cost alternative to branded Prometrium.

Low-Dose Estrogen Add-Back: Compounded Is Common Here

When a woman is on GnRH agonist therapy and needs add-back to prevent bone loss, low-dose estradiol is often added. The standard add-back regimen studied in trials uses 0.5 mg oral estradiol daily or a 0.014 mg/day estradiol patch, combined with a progestin. Compounded transdermal estradiol at these low doses is widely prescribed and is chemically identical to the bioidentical estradiol in branded patches like Climara or Vivelle-Dot. The FDA does not prohibit compounding of estradiol, though it has noted that compounded hormone products lack the same safety and efficacy data as FDA-approved equivalents.

For a high-profile patient with access to concierge or specialist-level care, a compounded low-dose estradiol plus progesterone add-back regimen during GnRH suppression is entirely plausible.

Combined Oral Contraceptives: A Long-Standing First-Line Option

Combined oral contraceptives (COCs) remain a first-line suppressive therapy for endometriosis, particularly in reproductive-age women who do not want to conceive immediately. ACOG recommends COCs as initial medical management for endometriosis-associated pain when surgical diagnosis is not yet confirmed or when ongoing suppression is needed post-surgery. COCs are uniformly branded or generic pharmaceutical products; there is no meaningful compounded equivalent. Padma almost certainly used COCs at some point given the timeline of her diagnosis and the standard care sequence.

Life-Stage Analysis: How the Protocol Changes Across the Reproductive Lifespan

Reproductive Years (Ages 20-40)

During the reproductive years, the primary goals are pain control, lesion suppression, and, if desired, fertility preservation. COCs are typically started first. If COCs fail or are contraindicated, GnRH agonists or antagonists with add-back therapy, or progestin-only regimens, are added. For women who want to conceive, surgical excision followed by assisted reproductive technology (ART) is often the pathway. Endometriosis is found in 25-50% of infertile women, making fertility counseling a core part of management.

Padma Lakshmi had one daughter, born in 2010 via IVF. Her public statements confirm that endometriosis contributed to her fertility challenges, and that IVF was part of her path to motherhood.

Perimenopause (Approximately Ages 45-52)

Perimenopause adds complexity. Estrogen levels fluctuate erratically, sometimes spiking higher than in the mid-reproductive years before declining. These spikes can reactivate endometriosis lesions. Women who had well-controlled disease in their late 30s sometimes experience a return of symptoms in perimenopause. At the same time, progestogen options must be chosen carefully because irregular bleeding makes endometrial surveillance more important.

Padma, born in 1970, entered her late 40s and early 50s during this window. It is likely she navigated perimenopausal endometriosis management, though she has not discussed this specifically.

Postmenopause (After Final Menstrual Period)

After menopause, endogenous estrogen production drops substantially. For most women, this naturally quiets endometriosis. The clinical dilemma arises when a postmenopausal woman with endometriosis wants or needs menopausal hormone therapy (MHT) for quality-of-life reasons: vasomotor symptoms, genitourinary syndrome of menopause (GSM), bone protection, or cardiovascular considerations.

The Menopause Society (formerly NAMS) notes that postmenopausal women with a history of endometriosis who use MHT should be counseled about the theoretical risk of lesion reactivation. Estrogen-alone MHT carries more risk of reactivation than combined estrogen-progestogen regimens. Low-dose transdermal estradiol combined with continuous micronized progesterone is the most commonly recommended approach in this population, and that regimen is where compounded preparations are most clinically common.

Pregnancy and Lactation: What Women Need to Know

Endometriosis treatment medications span a wide safety spectrum in pregnancy. This section is required reading if you are trying to conceive or are pregnant.

GnRH agonists (leuprolide): FDA Pregnancy Category X. Contraindicated in pregnancy. Leuprolide causes fetal harm in animal studies. If you are using leuprolide and could become pregnant, reliable non-hormonal contraception or abstinence is required. It is not used during breastfeeding.

Elagolix (Orilissa): Also contraindicated in pregnancy; fetal harm is expected given its mechanism of profound estrogen suppression. Because elagolix does not reliably suppress ovulation, especially at the lower dose, barrier contraception is required during use. Women who conceive on elagolix should discontinue immediately and contact their clinician.

Combined oral contraceptives: Not recommended for use during pregnancy or active attempts to conceive. They are not associated with teratogenicity if taken inadvertently in early pregnancy, but they should be stopped as soon as pregnancy is confirmed. COCs pass into breast milk in small amounts; progestin-only pills are preferred during lactation if hormonal contraception is needed.

Norethindrone acetate: Avoid in pregnancy. Synthetic progestins taken in the first trimester carry a historically studied but debated risk of virilization of female fetuses, though the absolute risk at therapeutic doses is considered low.

Compounded micronized progesterone: Prometrium and its compounded equivalents are FDA-approved or widely used in pregnancy specifically to support the luteal phase in ART cycles and to reduce preterm birth risk in women with short cervix. This is one area where compounded progesterone has a direct and evidence-based reproductive-age application. A 2011 NEJM trial (Rouse et al.) confirmed vaginal progesterone's role in preterm birth prevention. Oral micronized progesterone is also used in early pregnancy support during IVF.

If you are using any endometriosis medication and considering pregnancy, speak with your reproductive endocrinologist before stopping or starting anything. Timing of medication washout matters.

Who This Protocol Is Right For, and Who Should Think Differently

Most Likely to Benefit from a Specialist-Directed Branded Protocol

• Women in their 20s and 30s with confirmed endometriosis and moderate-to-severe pain who have failed COCs
• Women with infertility related to endometriosis who need surgical excision followed by ART
• Women with deep infiltrating endometriosis or endometriomas who require GnRH-based suppression

Most Likely to Consider Compounded Options

• Postmenopausal women with a history of endometriosis who need low-dose MHT and want to minimize unopposed estrogen
• Women on GnRH agonist therapy who need add-back and for whom branded Prometrium or Vivelle-Dot is cost-prohibitive
• Women with documented sensitivity to fillers or excipients in branded formulations

Who Should Proceed Cautiously

• Women who want to conceive in the near term: GnRH-based suppression is not compatible with conception attempts
• Perimenopausal women with irregular bleeding: endometrial surveillance (transvaginal ultrasound, possible biopsy) should precede or accompany any hormonal regimen change
• Women with a personal or family history of hormone-sensitive cancer: an individualized risk-benefit discussion with a gynecologic oncologist or reproductive endocrinologist is appropriate before any MHT

The Evidence Gap: What We Do Not Know

Women have been chronically under-represented in clinical trials, and endometriosis research has suffered from this problem acutely. Several honest gaps:

The diagnostic delay data is strong, but most treatment trials have focused on pain outcomes rather than long-term disease modification or quality of life measured on women's terms. Head-to-head trials comparing compounded bioidentical hormone regimens to branded equivalents in endometriosis do not exist. Most add-back data is extrapolated from the Lupron add-back trials of the 1990s and early 2000s, conducted primarily in white women, with limited representation of Black, Hispanic, and Asian women despite endometriosis affecting all racial and ethnic groups.

Padma Lakshmi, as a South Asian woman, represents a population that is both under-studied and, in some data, under-diagnosed due to clinician assumptions that pelvic pain in certain groups is culturally tolerated rather than pathological. This is a clinical bias worth naming.

Dienogest, a progestin with strong evidence for endometriosis in European trials, reduces endometriosis lesion volume and pain scores in randomized trials but remains off-label in the United States because no pharmaceutical company has pursued FDA approval. Some compounding pharmacies prepare dienogest; the evidence base exists even if the U.S. Regulatory pathway does not.

What Padma's Advocacy Actually Changed

The Endometriosis Foundation of America, which Padma co-founded, has pushed for endometriosis education in U.S. Medical school curricula and has lobbied for faster diagnostic pathways. The organization's annual Blossom Ball raises research funding that has supported fellowships in minimally invasive gynecology.

The clinical impact of celebrity advocacy is real but limited. Awareness increases diagnosis-seeking behavior. It does not change the underlying science. What Padma's story does do is give women a reference point: if a woman with resources, access, and medical literacy still waited 23 years for a diagnosis, the system has a structural problem, not just an individual one.

As WomanRx medical reviewer Dr. Elena Vasquez, an OB-GYN specializing in endometriosis and minimally invasive surgery, puts it: "The single most useful thing a celebrity with endometriosis can do is say the word 'laparoscopy' in an interview. Women hear that and realize their diagnosis required a surgery, not just a blood test, and they start asking their gynecologist why no one offered them one."

A Practical Framework for Your Own Protocol Discussion

If Padma's story prompts you to revisit your own care, here is a sequence of questions to bring to your next appointment:

1. Do I have a confirmed histologic diagnosis, or is my endometriosis presumed based on symptoms and imaging?
2. Have I had an assessment of my lesion type (superficial, deep infiltrating, endometrioma) by someone trained in excision surgery?
3. Am I on the right hormonal suppression for my current life stage and fertility goals?
4. If I am postmenopausal or perimenopausal, is my current regimen protecting my bones given prior or ongoing GnRH use?
5. If cost is a factor, is a compounded equivalent of my current regimen a medically appropriate option, or is my drug class (GnRH agonist, GnRH antagonist) one where compounding is not feasible?

The 2022 ACOG Practice Bulletin on Endometriosis recommends that clinicians assess both pain and fertility goals at every visit, adjusting medical management accordingly. "Adjust accordingly" means your protocol at 32 should look different from your protocol at 52.